A Single Mutation in K13 Predominates in Southern China and Is Associated with Delayed Clearance of Plasmodium falciparum Following Artemisinin Treatment

Journal of Infectious Diseases

Volumn 212, Issue 10, 2015, Pages 1629-1635

  Huang, Fang ^a,b   Takala Harrison, Shannon ^b   Jacob, Christopher G ^b   Liu, Hui ^c   Sun, Xiaodong ^c   Yang, Henglin ^c   Nyunt, Myaing M ^b   Adams, Matthew ^b   Zhou, Shuisen ^a   Xia, Zhigui ^a   Ringwald, Pascal ^a   Bustos, Maria Dorina ^a   Tang, Linhua ^a   Plowe, Christopher V ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b University of Maryland School of Medicine Center for Vaccine Development   (United States)

^c Yunnan Institute of Parasitic Diseases   (China)

Author keywords

Artemisinin resistance; China; Kelch 13; Malaria; Plasmodium falciparum

Indexed keywords

ARTEMISININ; ARTESUNATE; DIHYDROARTEMISININ PLUS PIPERAQUINE; KELCH PROTEIN; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ADULT; ARTICLE; CHINA; CHROMOSOME 13; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE SURVEILLANCE; DNA SEQUENCE; DRIED BLOOD SPOT TESTING; DRUG EFFICACY; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HALF LIFE TIME; HUMAN; K13 GENE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MUTATION RATE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PARASITE CLEARANCE; PARASITE PREVALENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTOZOAL GENETICS; TREATMENT DURATION; UNINDEXED SEQUENCE; ADOLESCENT; AGED; CHILD; DRUG EFFECTS; DRUG TOLERANCE; GENETICS; INFANT; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; MIDDLE AGED; MISSENSE MUTATION; PARASITOLOGY; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CHINA; DRUG TOLERANCE; FEMALE; GENOTYPE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MUTATION, MISSENSE; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDIES; PROTOZOAN PROTEINS; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84983059142     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv249     Document Type: Article

References (32)

1. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-67.
2. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619-20.
3. Huang F, Tang L, Yang H, Zhou S, Sun X, Liu H. Therapeutic efficacy of artesunate in the treatment of uncomplicated Plasmodium falciparum malaria and anti-malarial, drug-resistance marker polymorphisms in populations near the China-Myanmar border. Malar J 2012; 11:278.
4. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisininresistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379:1960-6.
5. Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012; 12:851-8.
6. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparummalaria.N Engl J Med 2014; 371:411-23.
7. Yeung S, Socheat D, Moorthy VS, Mills AJ. Artemisinin resistance on the Thai-Cambodian border. Lancet 2009; 374:1418-9.
8. Kyaw MP, Nyunt MH, Chit K, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLOS One 2013; 8:e57689.
9. Takala-Harrison S, Clark TG, Jacob CG, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci USA 2013; 110:240-5.
10. Cheeseman IH, Miller BA, Nair S, et al. A major genome region underlying artemisinin resistance in malaria. Science 2012; 336:79-82.
11. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014; 505:50-5.
12. Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis 2015; 211:670-9.
13. Thriemer K, Hong NV, Rosanas-Urgell A, et al. Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in Central Vietnam. Antimicrob Agents Chemother 2014; 58:7049-55.
14. Taylor SM, Parobek CM, DeConti DK, et al. Absence of putative Plasmodium falciparum artemisinin resistance mutations in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis 2015; 211:680-8.
15. Ghansah A, Amenga-Etego L, Amambua-Ngwa A, et al. Monitoring parasite diversity for malaria elimination in sub-Saharan Africa. Science 2014; 345:1297-8.
16. World Health Organization (WHO). Methods for the surveillance of antimalarial drug efficacy. Geneva, 2009.
17. World Health Organization (WHO). Malaria microscopy quality assurance manual-Version 1. Geneva, 2009.
18. Snounou G, Beck HP. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today 1998; 14:462-7.
19. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 2011; 10:339.
20. Ferreira PE, Culleton R, Gil JP, Meshnick SR. Artemisinin resistance in Plasmodium falciparum: what is it really? Trends Parasitol 2013; 29:318-20.
21. Cara Smith Gueye GNJHA. Emergency response to artemisinin in the greater Mekong subregion. 2014.
22. Wongsrichanalai C, Sibley CH. Fighting drug-resistant Plasmodium falciparum: the challenge of artemisinin resistance. Clin Microbiol Infect 2013; 19:908-16.
23. Witkowski B, Amaratunga C, Khim N, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis 2013; 13:1043-9.
24. Huang F, Tang L, Yang H, et al. Molecular epidemiology of drug resistance markers of Plasmodium falciparum in Yunnan Province, China. Malar J 2012; 11:243.
25. White NJ. Malaria: a molecular marker of artemisinin resistance. Lancet 2014; 383:1439-40.
26. Satimai W, Sudathip P, Vijaykadga S, et al. Artemisinin resistance containment project in Thailand. II: responses to mefloquine-artesunate combination therapy among falciparum malaria patients in provinces bordering Cambodia. Malar J 2012; 11:300.
27. Pradines B, Bertaux L, Pomares C, Delaunay P, Marty P. Reduced in vitro susceptibility to artemisinin derivatives associated with multiresistance in a traveller returning from South-East Asia. Malar J 2011; 10:268.
28. Wang RB, Zhang J, Zhang QF. Malaria baseline survey in four special regions of northern Myanmar near China: a cross-sectional study. Malar J 2014; 13:302.
29. Smith Gueye C, Newby G, Hwang J, et al. The challenge of artemisinin resistance can only be met by eliminating Plasmodium falciparum malaria across the Greater Mekong subregion. Malar J 2014; 13:286.
30. Roper C, Alifrangis M, Ariey F, et al. Molecular surveillance for artemisinin resistance in Africa. Lancet Infect Dis 2014; 14:668-70.
31. Conrad MD, Bigira V, Kapisi J, et al. Polymorphisms in K13 and falcipain- 2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLOS One 2014; 9:e105690.
32. Tun KM, Imwong M, Lwin KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis 2015; 15:415-21.